UBS analyst Danielle Antalffy initiated coverage of Zimmer Biomet with a Sell rating and $112 price target as part of a sector note on U.S. Medical Supplies and Devices. The firm models Zimmer’s 2022-2027 sales CAGR at 3.5%, with Zimmer delivering sub-4% organic growth each year, the analyst tells investors in a research note. While Zimmer has positive product cycles, UBS sees these as merely stemming share losses vs. driving sales gains.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ZBH:
- Zimmer Biomet initiated with a Sell at UBS
- Zimmer upgraded to Overweight on ‘conservative’ outlook at Piper Sandler
- Zimmer Biomet upgraded to Overweight from Neutral at Piper Sandler
- Zimmer Biomet Announces Quarterly Dividend for First Quarter of 2023
- Zimmer Biomet price target raised to $140 from $125 at Loop Capital